Portfolio News
2025/07/10
SinoMab (03681.HK) Globally First-in-Class SM03 (Suciraslimab) Achieves Breakthrough Preclinical Results in SLE,Demonstrating Positive Immune Modulation with Potential Multi-Organ Protection and Superior Long-Term Safety
